Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

 Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.

Highlights of today’s conference include:

• Expecting early completion of enrollment in PROGRESS, studying moderate AS patients, in early 2024
• Expecting data from EARLY TAVR, studying severe asymptomatic AS patients, at TCT 2024
• Commercializing EVOQUE tricuspid valve in Europe; expecting U.S. approval mid-2024
• Expecting CE Mark for SAPIEN M3 by the end of 2025
• Reaffirming 2023 financial guidance
• Projecting 2024 global sales of $6.3 - $6.6 billion; constant currency growth of 8% - 10%
• Estimating 2024 adjusted earnings per share of $2.70 - $2.80
• Projecting 2024 TAVR sales of $4.0 - $4.3 billion; constant currency growth of 8% - 10%
• Projecting 2024 TMTT sales of $280 - $320 million
• Announcing intent to spin-off Critical Care at the end of 2024

“We expect our sharpened focus in structural heart to drive sustainable growth in the years to come as we embark on a new era of innovation to address large unmet patient needs,” said Bernard Zovighian, Edwards’ CEO. “I’m pleased with our performance in 2023 as we have reinforced our TAVR leadership position with new clinical evidence and reached an inflection point with new approved mitral and tricuspid technologies. In 2024, we are projecting strong sales growth and look forward to launching breakthrough technologies and progressing on multiple important clinical trials.”

https://www.businesswire.com/news/home/20231207786271/en/